Literature DB >> 35140411

Spotting-based differentiation of functional dopaminergic progenitors from human pluripotent stem cells.

Jisun Kim1,2, Jeha Jeon1,2, Bin Song1,2, Nayeon Lee1,2, Sanghyeok Ko1,2, Young Cha1,2, Pierre Leblanc1,2, Hyemyung Seo3,4,5, Kwang-Soo Kim6,7.   

Abstract

To fully realize the potential of human pluripotent stem cells (hPSCs) for both therapeutic and research purposes, it is critical to follow an efficient and reliable in vitro differentiation method that is based on optimal physical, chemical and developmental cues. This highly reproducible protocol describes how to grow hPSCs such as human induced pluripotent and embryonic stem cells in a physically confined area ('spot') and efficiently differentiate them into a highly enriched population of healthy and functional midbrain dopamine progenitors (mDAPs) and midbrain dopamine neurons (mDANs). The protocol takes 28 d, during which cells first grow and differentiate in spots for 14 d and then are replated and further differentiated for a further 14 d as a monolayer culture. We describe how to produce mDAPs, control the quality of cells and cryopreserve mDAPs without loss of viability. Previously we showed that mDANs generated by this 'spotting'-based method exhibit gene expression and (electro)physiological properties typical of A9 mDANs lost in Parkinson's disease brains and can rescue motor defects when transplanted into the striatum of 6-hydroxydopamine-lesioned rats. This protocol is scalable for production of mDAPs under good manufacturing practice conditions and was also previously successfully used to generate cells for the first autologous cell replacement therapy of a patient with Parkinson's disease without the need for immune suppression. We anticipate this protocol could also be readily adapted to use spotting-based culture to further optimize the differentiation of hPSC to alternative differentiated cell types.
© 2022. Springer Nature Limited.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35140411      PMCID: PMC9511827          DOI: 10.1038/s41596-021-00673-4

Source DB:  PubMed          Journal:  Nat Protoc        ISSN: 1750-2799            Impact factor:   17.021


  46 in total

Review 1.  Pluripotent stem cell-based therapy for Parkinson's disease: Current status and future prospects.

Authors:  Kai-C Sonntag; Bin Song; Nayeon Lee; Jin Hyuk Jung; Young Cha; Pierre Leblanc; Carolyn Neff; Sek Won Kong; Bob S Carter; Jeffrey Schweitzer; Kwang-Soo Kim
Journal:  Prog Neurobiol       Date:  2018-04-11       Impact factor: 11.685

2.  Dopamine release from nigral transplants visualized in vivo in a Parkinson's patient.

Authors:  P Piccini; D J Brooks; A Björklund; R N Gunn; P M Grasby; O Rimoldi; P Brundin; P Hagell; S Rehncrona; H Widner; O Lindvall
Journal:  Nat Neurosci       Date:  1999-12       Impact factor: 24.884

Review 3.  The future of stem cell therapies for Parkinson disease.

Authors:  Malin Parmar; Shane Grealish; Claire Henchcliffe
Journal:  Nat Rev Neurosci       Date:  2020-01-06       Impact factor: 34.870

Review 4.  Cell therapeutics in Parkinson's disease.

Authors:  Olle Lindvall; Anders Björklund
Journal:  Neurotherapeutics       Date:  2011-10       Impact factor: 7.620

Review 5.  Epidemiology of Parkinson's disease.

Authors:  Lonneke M L de Lau; Monique M B Breteler
Journal:  Lancet Neurol       Date:  2006-06       Impact factor: 44.182

Review 6.  Developing dopaminergic cell therapy for Parkinson's disease--give up or move forward?

Authors:  Olle Lindvall
Journal:  Mov Disord       Date:  2013-02-11       Impact factor: 10.338

Review 7.  Cell-based therapies for Parkinson disease—past insights and future potential.

Authors:  Roger A Barker; Janelle Drouin-Ouellet; Malin Parmar
Journal:  Nat Rev Neurol       Date:  2015-08-04       Impact factor: 42.937

8.  Human autologous iPSC-derived dopaminergic progenitors restore motor function in Parkinson's disease models.

Authors:  Bin Song; Young Cha; Sanghyeok Ko; Jeha Jeon; Nayeon Lee; Hyemyung Seo; Kyung-Joon Park; In-Hee Lee; Claudia Lopes; Melissa Feitosa; María José Luna; Jin Hyuk Jung; Jisun Kim; Dabin Hwang; Bruce M Cohen; Martin H Teicher; Pierre Leblanc; Bob S Carter; Jeffrey H Kordower; Vadim Y Bolshakov; Sek Won Kong; Jeffrey S Schweitzer; Kwang-Soo Kim
Journal:  J Clin Invest       Date:  2020-02-03       Impact factor: 14.808

Review 9.  Fetal dopaminergic transplantation trials and the future of neural grafting in Parkinson's disease.

Authors:  Roger A Barker; Jessica Barrett; Sarah L Mason; Anders Björklund
Journal:  Lancet Neurol       Date:  2013-01       Impact factor: 44.182

10.  Long-term clinical outcome of fetal cell transplantation for Parkinson disease: two case reports.

Authors:  Zinovia Kefalopoulou; Marios Politis; Paola Piccini; Niccolo Mencacci; Kailash Bhatia; Marjan Jahanshahi; Håkan Widner; Stig Rehncrona; Patrik Brundin; Anders Björklund; Olle Lindvall; Patricia Limousin; Niall Quinn; Thomas Foltynie
Journal:  JAMA Neurol       Date:  2014-01       Impact factor: 18.302

View more
  1 in total

1.  Long-Term Evaluation of Intranigral Transplantation of Human iPSC-Derived Dopamine Neurons in a Parkinson's Disease Mouse Model.

Authors:  Sébastien Brot; Nabila Pyrenina Thamrin; Marie-Laure Bonnet; Maureen Francheteau; Maëlig Patrigeon; Laure Belnoue; Afsaneh Gaillard
Journal:  Cells       Date:  2022-05-10       Impact factor: 7.666

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.